Pharma and Biotech CRM Software Market Report 2026

The pharma and biotech crm software market size has grown strongly in recent years. It will grow from $4.72 billion in 2025 to $5.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing complexity of pharma sales operations, growing need for centralized customer data management, expansion of biotech commercialization activities, rising regulatory documentation requirements, increased adoption of digital engagement tools.

The pharma and biotech crm software market size is expected to see strong growth in the next few years. It will grow to $7.12 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing investments in ai-powered crm platforms, rising demand for real-time customer insights, expansion of cloud adoption among pharma companies, growing focus on data-driven decision-making, increasing integration with advanced analytics platforms. Major trends in the forecast period include increasing adoption of AI-driven sales analytics, growing use of personalized engagement platforms, expansion of cloud-based crm deployments, rising focus on omnichannel customer interaction, integration of advanced compliance and data security features.

The growing need for personalized medicine is expected to drive the growth of the pharma and biotech CRM software market in the coming years. Personalized medicine is a healthcare approach that tailors medical decisions and treatments to individual patients based on factors such as genetic profile, environmental influences, and lifestyle. The rising demand for personalized medicines is primarily fueled by increasing cancer rates and the growing prevalence of chronic diseases worldwide. This demand for customized therapies requires pharma and biotech CRM software to effectively manage patient data, monitor treatment outcomes, and support the efficient delivery of personalized healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit advocacy organization, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. The personalized treatments approved in 2023 also included seven cancer drugs and three therapies for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the pharma and biotech CRM software market.

Major companies operating in the pharma and biotech CRM software market are increasingly integrating artificial intelligence and machine learning technologies into their platforms, such as AI-powered personalized engagement solutions, to address the rising need for advanced customer relationship management tools tailored to pharmaceutical and biotechnology companies. AI-powered personalized engagement allows organizations to deliver relevant and targeted communication to healthcare professionals, patients, and other stakeholders. For example, in October 2023, Salesforce, Inc., a US-based cloud software provider, launched its Life Sciences Cloud to enhance patient engagement and clinical operations through data integration, automation, and trusted AI. This platform enables pharmaceutical and medical technology companies to optimize patient engagement, clinical workflows, commercial lifecycle management, and personalized interactions across the drug and medical device development process.

In January 2024, Nomadia, a France-based provider of cloud-based software-as-a-service solutions, acquired Nomadvantage for an undisclosed amount. This acquisition supports Nomadia’s strategy to broaden its cloud-based SaaS offerings and strengthen its market position. Nomadvantage is a France-based customer relationship management software company focused on serving the healthcare and pharmaceutical sectors.

Major companies operating in the pharma and biotech crm software market are Oracle Corporation, Salesforce.com Inc., IQVIA Holdings Inc., Cirrius Solutions Inc., Veeva Systems Inc., Aurea Software Inc., Indegene Private Limited, Close-Up International Limited, Interactive Medica S.A., StayinFront Inc., Axtria Inc., Navicon Consulting LLC, Aktana Inc., Bpmonline, Media-Soft Inc., Zephyr Health Inc., Synergistix Inc., Euris S.A., Inova Software Inc., Prolifiq Software Inc., Infonis International Corp., Ivy Software Development Services Pvt. Ltd., Pegasystems Inc., Microsoft Dynamics 365.

North America was the largest region in the pharma and biotech CRM software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma and biotech crm software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharma and biotech crm software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pharma and biotech CRM software market indirectly by increasing costs associated with imported IT infrastructure components, data storage hardware, and advanced analytics systems used in on-premises deployments. North America and Europe are most affected due to higher enterprise software implementation costs, while Asia-Pacific faces pricing pressure on imported enterprise IT solutions. These tariffs are increasing total cost of ownership and slowing migration from legacy systems. However, they are also accelerating the shift toward cloud-based CRM platforms, encouraging local software development, and strengthening regional digital service ecosystems.

The pharma and biotech crm software market research report is one of a series of new reports that provides pharma and biotech crm software market statistics, including pharma and biotech crm software industry global market size, regional shares, competitors with a pharma and biotech crm software market share, detailed pharma and biotech crm software market segments, market trends and opportunities, and any further data you may need to thrive in the pharma and biotech crm software industry. This pharma and biotech crm software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharma and biotech CRM software is a specialized solution developed to help pharmaceutical and biotechnology companies efficiently manage customer relationships, data, and interactions. This software enables organizations to deliver a consistent and personalized customer experience by offering a comprehensive view of customer engagement, thereby supporting stronger and more effective relationships.

The primary technology types of pharma and biotech CRM software include artificial intelligence-based customer relationship management (CRM) and conventional customer relationship management systems. AI-driven pharma and biotech CRM software applies artificial intelligence and machine learning techniques to analyze customer data, generate actionable insights, and automate routine processes. These solutions can be deployed through on-premises or cloud-based models and are used by large enterprises as well as small and medium enterprises within the pharmaceutical and biotechnology sectors.

The pharma and biotech CRM software market consists of revenues earned by entities through services such as customer relationship management, sales force automation, marketing automation, mobile and remote access, and integration with the healthcare ecosystem. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma and biotech CRM market also includes sales of lead management software, email marketing software, call center software, event management software, and training and education software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.